<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071198</url>
  </required_header>
  <id_info>
    <org_study_id>201702230001</org_study_id>
    <nct_id>NCT03071198</nct_id>
  </id_info>
  <brief_title>Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy</brief_title>
  <official_title>Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy for T3-4N0-2M0 Middle and Lower Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical effect of neoadjuvant hierarchical treatment based on chemotherapy for T3-4N0-2M0
      middle and lower rectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By setting 3-Year disease-free survival (DFS) as main objective, the treatment strategy will
      be optimizing as neoadjuvant chemotherapy alone and chemo-radio-chemo sequential treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This strategy is called &quot;neoadjuvant hierarchical treatment&quot; based on chemotherapy for rectal cancer. All patients with T3-4N0-2M0 middle and lower rectal caner will firstly receive neoadjuvant chemotherapy consisting of four cycles of XELOX. After four cycles, the patients achieved cCR or cPR will be perform the operation. And the patients who can not achieve cCR or cPR after the four cycles, then concurrent chemoradiotherapy will be added.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>the treatment strategy will be optimizing as neoadjuvant chemotherapy alone and chemo-radio-chemo sequential treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgery related mortality and complication</measure>
    <time_frame>3 years</time_frame>
    <description>Surgery related mortality and complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate of R0</measure>
    <time_frame>3 years</time_frame>
    <description>Resection rate of R0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete remission (pCR) rate</measure>
    <time_frame>3 years</time_frame>
    <description>Pathologic complete remission (pCR) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance after neoadjuvant treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Tolerance after neoadjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictor efficacy of neoadjuvant chemotherapy for DFS</measure>
    <time_frame>3 years</time_frame>
    <description>Predictor efficacy of neoadjuvant chemotherapy for DFS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>Preoperative neoadjuvant CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative neoadjuvant CT-RCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemo-radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME</intervention_name>
    <description>Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.
At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations.</description>
    <arm_group_label>Preoperative neoadjuvant CT</arm_group_label>
    <arm_group_label>Preoperative neoadjuvant CT-RCT</arm_group_label>
    <arm_group_label>Concurrent chemo-radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemo-radiotherapy</intervention_name>
    <description>Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day</description>
    <arm_group_label>Preoperative neoadjuvant CT-RCT</arm_group_label>
    <arm_group_label>Concurrent chemo-radiotherapy</arm_group_label>
    <other_name>neoadjuvant RCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant CT</intervention_name>
    <description>CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks</description>
    <arm_group_label>Preoperative neoadjuvant CT</arm_group_label>
    <arm_group_label>Preoperative neoadjuvant CT-RCT</arm_group_label>
    <other_name>neoadjuvant chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant CT</intervention_name>
    <description>CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks</description>
    <arm_group_label>Preoperative neoadjuvant CT</arm_group_label>
    <arm_group_label>Preoperative neoadjuvant CT-RCT</arm_group_label>
    <arm_group_label>Concurrent chemo-radiotherapy</arm_group_label>
    <other_name>adjuvant chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria

               -  Pathologically confirmed to be rectal adenocarcinoma.

               -  Distance &lt; 10cm from the end of the tumor to the anal verge found on colonoscopy

               -  Tumor in stage T3-4N0-2 (pelvic MRI evaluation)

               -  Patients without distant metastases (such as liver and peritoneum, lungs, aortic
                  lymph nodes)

               -  Patients with Karnofsky score greater ≥ 70

               -  WBC &gt; 3.5 x 109/ml , PLT &gt; 10 x 109/ml , TBIL&lt;22.2 umol/l , BUN &lt;7.14mmol/l ,
                  Cr&lt;132umol/l or Ccr &gt; 50ml/min (Evaluated using the Cockcroft-Gault formula:
                  Creatinine clearance (male) = {(140 - age) x LBM (kg)} / {plasma creatinine
                  (mg/dl) x 72} ; Creatinine clearance (female) = 0.85 x {(140 - age) x LBM(kg)}/ {
                  plasma creatinine (mg/dl) x 72})

               -  Patients must sign the informed consent form

               -  Female subjects must be contraceptive during the trial

               -  Patients who did not receive any form of chemotherapy and radiotherapy

               -  No other important related diseases (such as other tumors, severe heart disease
                  and central nervous system diseases, etc.)

               -  Age must be equal or more than 20 and must be equal or less than 70

          -  Exclusion criteria

               -  Previously received radiation therapy, chemotherapy or anti-tumor biological
                  therapy

               -  Previously received immuno-suppressive therapy

               -  Participation in interventional clinical trial over the past time

               -  Suffering from malignant colonic neoplasms simultaneously

               -  With peripheral neuropathy(above WHO I level)

               -  Affected cognitive abilities because of neurological or psychiatric abnormalities
                  Including central nervous system metastasis

               -  Medical history of severe allergies or allergic constitution

               -  Severe pulmonary or heart disease history

               -  Female patients who are in pregnancy or lactation and refuse contraception

               -  Previously with other malignant tumors

          -  Exit criteria

               -  Occurrence of bleeding, obstruction, perforation and other complications

               -  Occurrence of distant metastasis during the period of neoadjuvant therapy

               -  Adverse reactions, not be tolerated and do not want to continue to receive
                  treatment

               -  Patients voluntarily quit

               -  Capecitabine-related Grade 4 Hand-Foot Syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>binbin cui</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>binbin Cui, Doctor</last_name>
    <phone>+86-13351112888</phone>
    <email>Cuibb2017@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yanlong Liu, Doctor</last_name>
    <phone>+86-13845082914</phone>
    <email>liuyanlong1979@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>binbin cui</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Binbin Cui</investigator_full_name>
    <investigator_title>Director of colorectal surgery</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

